Cytosorbents (CTSO) Stock Overview
Engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
CTSO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Cytosorbents Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$1.39 |
| 52 Week Low | US$0.60 |
| Beta | 1.4 |
| 1 Month Change | 14.09% |
| 3 Month Change | 3.51% |
| 1 Year Change | -35.67% |
| 3 Year Change | -77.39% |
| 5 Year Change | -92.17% |
| Change since IPO | -98.38% |
Recent News & Updates
Recent updates
Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower
Nov 13
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
Nov 08Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?
Aug 09Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce
Jul 02
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Jan 17The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Oct 01Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
Jul 04Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Mar 16Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Jan 06Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
Nov 10Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price
Jul 13Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
May 16Shareholder Returns
| CTSO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -11.3% | -4.1% | -1.6% |
| 1Y | -35.7% | -9.9% | 17.7% |
Return vs Industry: CTSO underperformed the US Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: CTSO underperformed the US Market which returned 20.4% over the past year.
Price Volatility
| CTSO volatility | |
|---|---|
| CTSO Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CTSO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CTSO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 149 | Phil Chan | www.cytosorbents.com |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.
Cytosorbents Corporation Fundamentals Summary
| CTSO fundamental statistics | |
|---|---|
| Market cap | US$45.58m |
| Earnings (TTM) | -US$10.27m |
| Revenue (TTM) | US$36.98m |
Is CTSO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTSO income statement (TTM) | |
|---|---|
| Revenue | US$36.98m |
| Cost of Revenue | US$10.80m |
| Gross Profit | US$26.18m |
| Other Expenses | US$36.45m |
| Earnings | -US$10.27m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 25, 2026
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 70.80% |
| Net Profit Margin | -27.77% |
| Debt/Equity Ratio | 161.5% |
How did CTSO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 13:54 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytosorbents Corporation is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Sean Lee | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |